the company is building technology that enables scalable, true 3D mapping of gene expression inside intact biological samples—moving beyond the limitations of traditional 2D tissue slices
CubaseBio has raised €5.9M across 1 funding round from 7 investors, most recently a round in Feb 2026. Based in Stockholm, Sweden; active in Healthtech. Data as of 7 Aug 2026.
Timing: too soon vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-02-19 | Other | €5.9M |
| Almi Invest,Angel Investors,European Innovation Council,Illumina Ventures,Life Science Invest,Nordic Science Investments+1 more |
| View deal → |
